TGF-beta may potentially be successful in the treatment of colon cancer since it inhibits the proliferation of responsive human colon carcinoma cells and elicits differentiation-like effects. However, approximately 50% of colon carcinoma cells tested were unresponsive to TGF-beta. The overall goal of this proposal is to expand a previously-established model system for TGF-beta resistance in human colon carcinoma cells, and to utilize this model system to identify possible mechanisms underlying TGF-beta resistance. The result obtained from this proposal will identify targets for the development of drugs which will either mimic the inhibitory effects of TGF-beta on epithelial colon tumors or which will eliminate the development of resistance to growth regulation by TGF-beta. Areas of investigation aimed at elucidating mechanisms of action of and/or of resistance to TGF-beta include: (1) Characterization of receptor binding and receptor subtypes in the resistant and sensitive clones, (2) Investigation of the involvement or alteration of G proteins and of ras oncoproteins in transduction of cellular signals generated by TGF-beta (G proteins appear to be involved in TGF-beta-induced mitogenesis in fibroblast cells), and (3) Investigation of alterations in the regulation of expression of the nuclear proto-oncogenes c-myc, c-fos, and c-jun (and their protein products) to identify any alterations in these molecular links between signal transduction and transcriptional regulation. Previous work indicated that 3/4 of initially-identified TGF-Beta-resistant clones over-expressed c-myc, an event which has been shown to alter TGF-Beta responsiveness in other cells. Additional experiments will be focused on the cellular environment as a mediator of altered TGF-beta responsiveness. Overproduction of, or responsiveness to, growth stimulatory autocrine factors in the resistant clones may outweigh any potential inhibitory effects of TGF-beta. Therefore, involvement of EGF, TGF-alpha and the EGF receptor in TGF-beta resistance will be addressed.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
7R29CA051452-03
Application #
3459771
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1989-12-01
Project End
1994-11-30
Budget Start
1991-07-16
Budget End
1991-11-30
Support Year
3
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Pennsylvania State University
Department
Type
Schools of Medicine
DUNS #
129348186
City
Hershey
State
PA
Country
United States
Zip Code
17033